Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Push who wrote (51)	5/31/1999 1:58:00 PM
From: Steve Lokness	Read Replies (2) \| Respond to of 360

Must be the lull before the storm? GLGC probe question: As genetic testing becomes more and more important, it is also apparent that more than one test will likely be needed for each disease/person. Does GLGC's flow through chip have potential as a diagnostic tool for testing of more than one test? If VGIN can test for several HIV variations at once (doesn't each variation require a separate probe?) it seems a natural progression of things that test could be developed for multiple genetic variations. If not the flow through chip maybe HYSQ's? hyseq.com Steve

To: Steve Push who wrote (51)	6/4/1999 7:53:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 360

Steve: Something to help you with your research??....... Friday June 4, 6:13 pm Eastern Time Company Press Release SOURCE: Oxford Gene Technology Limited OGT Files Patent Infringement Suits Against Affymetrix In UK and US OXFORD, England, June 4 /PRNewswire/ -- Oxford Gene Technology Limited (OGT), the UK based company set up to exploit the DNA microarray patents of Professor Ed Southern, Professor of Biochemistry at the University of Oxford, has filed law suits in the UK and US against Affymetrix (Nasdaq: AFFX - news) alleging infringement of European Patent numbered 0-373-203 entitled ''Analysing Polynucleotide Sequences'' and US Patent numbered 5,700,637 entitled ''Apparatus and Method for Analysing Polynucleotide Sequences and Method of Generating Oligonucleotide Arrays''. These fundamental DNA microarray patents, based on earlier research by Professor Southern, were filed in 1989. OGT believes that Affymetrix has been knowingly infringing its US Patent since the Patent issue in December 1997 and that it is also now making substantial sales in Europe, where OGT also has broad patent protection. OGT is seeking substantial compensation for what it believes are at least 17 months of infringing sales, which are still continuing. Affymetrix has been relying on a consortium clause in OGT's 1996 Licence Agreement with Beckman Coulter in its claim to have obtained access to OGT's patents. OGT does not believe it is obliged to grant a licence to Affymetrix under this Agreement and is seeking a declaration against Affymetrix and Beckman in the UK. OGT has indicated that it is prepared to grant Affymetrix a licence under terms satisfactory to OGT, but believes Affymetrix has been trying to use a legal device to obtain better terms. OGT holds fundamental patents for DNA microarrays and related technologies and is determined to protect and, where necessary, enforce, its intellectual property rights. Issued for and on behalf of Oxford Gene Technology Limited and Manches Solicitors by HCC De Facto Group plc. SOURCE: Oxford Gene Technology Limited